- Cool Tool – PRIME-XV® T Cell CDM – First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 2 days ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 1 week ago
- Continuous Processing Optimization with Smarter ToolsPosted 1 week ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 1 week ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 1 week ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 2 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
- Cell Culture Monitoring – A Critical Component for Quality by Design in Cell TherapyPosted 3 weeks ago
The future of cell culture development? Part I
As we learn more and more about the detailed workings of cells used in biomanufacturing, methods to modify these workings are developed. This recent article from GEN describes some technologies that were unavailable to cell culture scientists in the past; glycoengineering and site-specific integration.
The sequencing of the CHO genome should provide even more opportunities to improve biopharmaceutical production. Several groups have sequenced CHO cell lines; GT Life Sciences collaborated with BGI to sequence CHO-K1 [announcement pdf], while Selexis collaborated with several Swiss institutions to sequence their proprietary “SURECHO-M” line.
These are just a few examples of techniques that can be used to develop cell lines to produce biopharmaceuticals. It should be interesting to see how regulatory agencies treat drug applications that use cell lines that were developed using advanced techniques such as these.